Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is a clinical trial sponsor. It has no active clinical trials as lead sponsor; its trials since 2021 were across 16 therapeutic areas. Since 2021 it has completed 369 trials and stopped 52 early.
Trial track record · since 2021
Pipeline · 0 active trials
No active trials with this company as lead sponsor.
Questions about Pfizer's Upjohn has merged with Mylan to form Viatris Inc
Pfizer's Upjohn has merged with Mylan to form Viatris Inc has no active clinical trials as lead sponsor on ClinicalTrials.gov. Since 2021 it has completed 369 trials and stopped 52 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Pfizer's Upjohn has merged with Mylan to form Viatris Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2023-10-10.
Approve Suite is not affiliated with Pfizer's Upjohn has merged with Mylan to form Viatris Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.